Trials / Completed
CompletedNCT01733004
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 42 (actual)
- Sponsor
- Merrimack Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MM-141 |
Timeline
- Start date
- 2012-11-01
- Primary completion
- 2016-01-01
- First posted
- 2012-11-26
- Last updated
- 2016-08-04
Locations
4 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT01733004. Inclusion in this directory is not an endorsement.